Canaccord Genuity Reiterates Buy Rating on Viking Therapeutics, Inc. (VKTX)

Market Context

Viking Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $33.11 with a market capitalization of $4.2B.

Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Viking Therapeutics, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Viking Therapeutics, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 30, 2026	Canaccord Genuity	Buy	N/A
May 28, 2026	Lake Street	Buy	N/A
Apr 30, 2026	Cantor Fitzgerald	Overweight	N/A
Mar 23, 2026	HC Wainwright & Co.	Buy	N/A
Nov 12, 2025	Canaccord Genuity	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View VKTX Stock Page